Premium Nahrungsergänzungsmittel | artgerecht

Von Hippel-Lindau-Czermak Syndrome – Overview & Treatment

Von Hippel-Lindau-Czermak syndrome is a rare hereditary condition that causes tumors and cysts to develop in multiple organs, primarily affecting the brain, spinal cord, eyes, and kidneys.

Regular tips about health Regular tips about health

Things worth knowing about "Von Hippel-Lindau-Czermak Syndrome"

Von Hippel-Lindau-Czermak syndrome is a rare hereditary condition that causes tumors and cysts to develop in multiple organs, primarily affecting the brain, spinal cord, eyes, and kidneys.

What is Von Hippel-Lindau-Czermak Syndrome?

Von Hippel-Lindau-Czermak syndrome (VHL syndrome) is a rare, inherited disorder belonging to the group of hereditary tumor syndromes. It is caused by a mutation in the VHL tumor suppressor gene located on chromosome 3 and follows an autosomal dominant inheritance pattern. This means that a mutation in just one copy of the gene is sufficient to cause the disease. The syndrome is named after physicians Eugen von Hippel, Arvid Lindau, and Johann Nepomuk Czermak, who each made significant contributions to its clinical description.

VHL syndrome leads to the uncontrolled growth of both benign and malignant tumors as well as cysts in various organs. A hallmark feature is the development of hemangioblastomas -- highly vascularized tumors -- in the central nervous system and the retina of the eye.

Causes and Genetics

The underlying cause is a germline mutation in the VHL gene. Under normal circumstances, this gene encodes a protein that regulates cell growth and controls the formation of new blood vessels (angiogenesis). When this function is lost, uncontrolled cell proliferation and excessive vascularization occur.

Inheritance: autosomal dominant (an affected parent has a 50% chance of passing the mutation to each child)
De novo mutations (without affected parents) are possible but less common
Prevalence: approximately 1 in 36,000 individuals is affected

Symptoms

The symptoms of VHL syndrome vary widely depending on which organs are involved. The disease typically manifests in early adulthood but can also present during childhood.

Central Nervous System

Hemangioblastomas of the cerebellum, brainstem, or spinal cord: headaches, balance disorders, coordination problems, weakness or paralysis

Eyes

Retinal hemangioblastomas (formerly: angiomatosis retinae): visual disturbances up to and including blindness; often the first symptom in young adults

Kidneys

Clear cell renal cell carcinoma and renal cysts: frequently bilateral, with an elevated risk of metastasis

Adrenal Glands

Pheochromocytomas: hypertensive crises, palpitations, sweating, headaches

Pancreas

Pancreatic cysts and neuroendocrine tumors: abdominal pain, digestive disturbances, and in advanced stages, diabetes mellitus

Inner Ear

Endolymphatic sac tumors: hearing loss, tinnitus, dizziness

Diagnosis

Diagnosis of VHL syndrome is established through clinical evaluation and molecular genetic testing. Key investigations include:

Genetic testing: Detection of the VHL gene mutation via blood test (gold standard)
MRI of the brain and spinal cord: Screening for hemangioblastomas
Ophthalmoscopy (fundoscopy): Assessment of the retina for vascular lesions
Abdominal ultrasound, CT, or MRI: Evaluation of the kidneys, adrenal glands, and pancreas
Laboratory tests: Urinary or plasma catecholamines and metanephrines (to rule out pheochromocytoma)

In individuals with a known family history, regular surveillance screenings are recommended starting in childhood.

Treatment

There is currently no curative treatment for the underlying genetic mutation. Therapy focuses on preventing complications and treating tumors at an early stage.

Surgical Treatment

Surgical removal of CNS hemangioblastomas when symptomatic or showing progressive growth
Partial nephrectomy or nephrectomy for renal cell carcinoma
Resection of adrenal pheochromocytomas

Ophthalmic Treatment

Laser photocoagulation or cryotherapy of retinal hemangioblastomas to prevent vision loss

Medical Therapy

Belzutifan (HIF-2alpha inhibitor): approved by the FDA in 2021 and by the EMA in 2023 for treatment of VHL-associated tumors not requiring immediate surgery
VEGF inhibitors and mTOR inhibitors for specific tumor manifestations

Ongoing Surveillance

Due to multi-organ involvement, lifelong interdisciplinary follow-up care is essential. Regular monitoring by neurologists, ophthalmologists, urologists, endocrinologists, and clinical geneticists is strongly recommended.

Prognosis

The prognosis of VHL syndrome depends greatly on the timing of diagnosis and the consistency of follow-up care. Early detection through regular screening can significantly improve quality of life and prevent life-threatening complications. Renal cell carcinoma is the most common cause of death in affected individuals if not treated in a timely manner.

References

Lonser RR et al. - von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-2067.
Maher ER et al. - Von Hippel-Lindau disease: a clinical and scientific review. European Journal of Human Genetics. 2011;19(6):617-623.
National Institutes of Health (NIH) - Von Hippel-Lindau Disease Information Page. https://www.ninds.nih.gov (accessed 2024)

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category